IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 2.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 31,643 shares of the medical research company’s stock after selling 951 shares during the period. Janney Montgomery Scott LLC’s holdings in IQVIA were worth $5,732,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. HighTower Advisors LLC lifted its holdings in IQVIA by 2.4% in the 1st quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock worth $1,168,000 after buying an additional 118 shares in the last quarter. Prudential PLC acquired a new position in IQVIA in the 1st quarter worth $741,000. Baird Financial Group Inc. lifted its holdings in IQVIA by 2.3% in the 1st quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock worth $23,021,000 after buying an additional 2,201 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in IQVIA by 59.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock worth $90,000 after buying an additional 144 shares in the last quarter. Finally, Covestor Ltd lifted its holdings in IQVIA by 82.2% in the 1st quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock worth $128,000 after buying an additional 250 shares in the last quarter. Institutional investors and hedge funds own 86.20% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $208.49 on Tuesday. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 2.29. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $263.95. The firm has a 50-day simple moving average of $210.65 and a 200 day simple moving average of $210.94. The company has a market cap of $38.72 billion, a PE ratio of 33.96, a P/E/G ratio of 2.12 and a beta of 1.37.

IQVIA (NYSE:IQV – Get Rating) last posted its earnings results on Wednesday, October 26th. The medical research company reported $2.23 EPS for the quarter, topping the consensus estimate of $2.19 by $0.04. IQVIA had a net margin of 8.26% and a return on equity of 31.36%. The firm had revenue of $3.56 billion during the quarter, compared to analysts’ expectations of $3.55 billion. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 9.35 EPS for the current year.

Analyst Ratings Changes

IQV has been the topic of a number of recent analyst reports. Mizuho cut their price objective on shares of IQVIA from $270.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, November 10th. StockNews.com assumed coverage on shares of IQVIA in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Citigroup downgraded shares of IQVIA from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $275.00 to $245.00 in a research report on Thursday, November 17th. Barclays boosted their target price on shares of IQVIA from $215.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, October 27th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of IQVIA from $290.00 to $270.00 in a research report on Tuesday, October 18th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $257.13.

IQVIA Profile

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.